NRx Pharmaceuticals (NASDAQ:NRXP) Earns “Buy” Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $34.00 price objective on the stock.

NRXP has been the topic of several other research reports. Ascendiant Capital Markets reaffirmed a “buy” rating and issued a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Finally, HC Wainwright upped their target price on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

NRx Pharmaceuticals Stock Up 13.1%

Shares of NRXP opened at $2.41 on Tuesday. The company has a 50-day moving average price of $1.95 and a two-hundred day moving average price of $2.44. The stock has a market cap of $79.70 million, a price-to-earnings ratio of -1.73 and a beta of 1.97. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.28. The company had revenue of $0.98 million during the quarter, compared to the consensus estimate of $7.53 million. Equities research analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Anson Funds Management LP raised its position in NRx Pharmaceuticals by 26.2% in the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after purchasing an additional 420,129 shares during the last quarter. AdvisorShares Investments LLC grew its holdings in shares of NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC grew its holdings in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares during the last quarter. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals in the third quarter valued at $39,000. Finally, Vanguard Group Inc. increased its stake in shares of NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting NRx Pharmaceuticals

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: Company pursuing both ANDA (generic) and NDA (new drug) pathways for NRX‑101, signaling potential for near‑term commercial opportunities and a dual regulatory strategy that could expand addressable markets if either filing succeeds. NRx Pharmaceuticals (NRXP) looks to score double with ANDA and NDA filings for NRX-101
• Positive Sentiment: Q4 report delivered an EPS beat (reported $0.19 vs. consensus -$0.09), which likely surprised traders and helped lift sentiment despite mixed top‑line results. NRx Pharmaceuticals earnings / conference call
• Positive Sentiment: Two firms (D. Boral Capital and BTIG) reaffirmed “buy” ratings with high price targets ($34 and $25), which can amplify buying interest and momentum in a small‑float name. Benzinga
• Positive Sentiment: Full‑year 2025 update highlighted reduced operating expenses, $7.8M cash at year‑end and management’s view that current resources + revenues/ATMs should support operations through 2026 — improving near‑term runway visibility. NRx Reports Full‑Year 2025 Results
• Neutral Sentiment: Full Q4 2025 earnings call transcript is available for detail and could shape investor views depending on management guidance and Q&A. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Multiple short‑interest reports for March show zero shares / NaN changes — likely a data/reporting error. Short‑interest info is currently unreliable and shouldn’t be over‑interpreted until corrected.
• Negative Sentiment: Revenue for the quarter ($0.98M) materially missed consensus (~$7.5M), a notable weakness versus estimates that could temper the EPS beat’s positive effect. Press Release / Full Results
• Negative Sentiment: Analyst consensus still models a negative EPS for the year (group forecast ~-1.75), implying continued expectations for losses absent material commercial progress.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.